Improving cardiovascular magnetic resonance access in low- and middle-income countries for cardiomyopathy assessment: rapid cardiovascular magnetic resonance

Abstract

Aims To evaluate the impact of a simplified, rapid cardiovascular magnetic resonance (CMR) protocol embedded in care and supported by a partner education programme on the management of cardiomyopathy (CMP) in low- and middle-income countries (LMICs). Methods and results Rapid CMR focused particularly on CMP was implemented in 11 centres, 7 cities, 5 countries, and 3 continents linked to training courses for local professionals. Patients were followed up for 24 months to assess impact. The rate of subsequent adoption was tracked. Five CMR conferences were delivered (920 attendees—potential referrers, radiographers, reporting cardiologists, or radiologists) and five new centres starting CMR. Six hundred and one patients were scanned. Cardiovascular magnetic resonance indications were 24% non-contrast T2* scans [myocardial iron overload (MIO)] and 72% suspected/known cardiomyopathies (including ischaemic and viability). Ninety-eighty per cent of studies were of diagnostic quality. The average scan time was 22 ± 6 min (contrast) and 12 ± 4 min (non-contrast), a potential cost/throughput reduction of between 30 and 60%. Cardiovascular magnetic resonance findings impacted management in 62%, including a new diagnosis in 22% and MIO detected in 30% of non-contrast scans. Nine centres continued using rapid CMR 2 years later (typically 1–2 days per week, 30 min slots). Conclusions Rapid CMR of diagnostic quality can be delivered using available technology in LMICs. When embedded in care and a training programme, costs are lower, care is improved, and services can be sustained over time. Key question Key finding Take-home message

Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images

“…More recently, multimodal imaging with magnetic resonance imaging, including T1 mapping, extracellular volume (ECV) quantification, 11,14 or positron emission tomography with radiotracers tracking myocardial function, metabolism, and tissue repair have also shown value in pre-clinical or small clinical studies. 14,35,36 However, access to these technologies varies across different parts of the world, [37][38][39] underlining an unmet need for efficient cardiovascular risk stratification that can be performed at the point-of-care using readily accessible, yet personalized technologies.…”

Kardiovaskuläre MRT in der Bewertung von Kardiomyopathien – ein aktueller Überblick

“…Das T2*-Mapping ermöglicht eine nicht invasive Quantifizierung der Eisenablagerungen im Herzmuskel, was eine frühzeitige Erkennung und Behandlung von kardialen Komplikationen erlaubt [57]. Dies ist hinreichend validiert worden und hat breite klinische Anwendung, was zur Kostensenkung bei den assoziierten Erkrankungen in Ländern mit niedrigem Einkommen geführt hat [58]. Der Ansatz hat nicht nur zum weitgehenden Verschwinden der Leberbiopsie für die Verlaufskontrolle der Eisenüberladung geführt, sondern konnte auch zeigen, dass Deferipron in der Kontrolle oder der myokardialen Eisenlast überlegen ist.…”

Hypertrophic Cardiomyopathy Diagnosis and Treatment in High- and Low-Income Countries: A Narrative Review

“…Cardiovascular magnetic resonance is the gold standard for many cardiac pathologies and has shown to be superior to other imaging techniques [ 30 ]. Despite the essential role of MRI in diagnosis and its many advantages over other imaging modalities, it has been estimated that 66% of the world does not have access to this diagnostic tool - low-income countries are most affected [ 31 ].…”